Cullinan Pearl
Cambridge, Massachusetts, United States
About Cullinan Pearl
Cullinan Pearl develops an orally available tyrosine kinase inhibitor to target Epidermal Growth Factor Receptor exon 20 mutations. Cullinan Pearl is a subsidiary of Cullinan Oncology.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Funding stage: M&A
- Last round: Series A (Feb 2019)
- Website: cullinanoncology.comcullinan-pearl
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/cullinan-pearl-2464839 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.